Bolla M, Chedin M, Chambaz E, Gabelle P
Sem Hop. 1984 Jan 19;60(2):91-6.
Estradiol (ER) and progesterone (PR) receptor assay was performed in breast cancer specimens from 133 women, 31 to 83 years of age. Mean ER levels increase significantly from one ten year age group to the next, ranging from 59.9 + 46.2 femtomoles/mg cytosolic protein in the 30-40 year group to 627 + 479 fmol/mg protein in the 89-90 year group. Mean ER values were found to be 50 + 20.4 fmol/mg protein in premenopausal patients and 176.8 + 55 after menopause. PR concentrations were similar in pre and post-menopausal patients (62.2 + 25.8 and 73.8 + 33.8 fmol/mg protein respectively. Receptor level was not correlated with T.N.M. clinical staging or lymph node involvement. Analysis of ER and PR levels according to histologic (Scarff and Bloom) grading showed a positive correlation between receptor concentration and cellular differentiation. Disease-free survival rate two years after initial therapy was significantly higher in ER positive cases (p = 0.01), although 79% of ER negative patients received adjuvant systemic therapy. In PR positive cases, this difference nearly disappears (p = 0.09), even though 70% of PR negative patients were submitted to adjuvant systemic therapy. Chemotherapy is therefore justified in RE negative patients who carry a poor prognosis.
对133名年龄在31至83岁的女性乳腺癌标本进行了雌二醇（ER）和孕酮（PR）受体检测。平均ER水平从一个十年年龄组到下一个年龄组显著升高，范围从30 - 40岁组的59.9 + 46.2飞摩尔/毫克胞浆蛋白到80 - 90岁组的627 + 479飞摩尔/毫克蛋白。发现绝经前患者的平均ER值为50 + 20.4飞摩尔/毫克蛋白，绝经后为176.8 + 55。绝经前和绝经后患者的PR浓度相似（分别为62.2 + 25.8和73.8 + 33.8飞摩尔/毫克蛋白）。受体水平与T.N.M.临床分期或淋巴结受累无关。根据组织学（斯卡夫和布鲁姆）分级分析ER和PR水平显示受体浓度与细胞分化之间呈正相关。初始治疗两年后的无病生存率在ER阳性病例中显著更高（p = 0.01），尽管79%的ER阴性患者接受了辅助全身治疗。在PR阳性病例中，这种差异几乎消失（p = 0.09），尽管70%的PR阴性患者接受了辅助全身治疗。因此，对于预后不良的ER阴性患者，化疗是合理的。
